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Background: Expansions of myeloid-derived suppressor cells (MDSCs) have been identified in human solid tumors,
including colorectal cancer (CRC). However, the nature of these tumor-associated MDSCs and their interactions with
tumor cells in CRC are still poorly understood.
Methods: The percentages and phenotype of MDSCs in peripheral blood and tumorous and paraneoplastic tissues
from CRC patients, as well as the clinical relevance of these MDSCs, were assessed. Age-matched healthy donors were
included as controls. The interaction between MDSCs and T cells or tumor cells was investigated in a coculture system
in vitro, and the molecular mechanism of the effect of MDSCs on T cells or tumor cells was evaluated.
Results: We discovered that CRC patients had elevated levels of CD33+CD11b+HLA-DR− MDSCs in primary tumor tissues
and in peripheral blood, and the elevated circulating MDSCs were correlated with advanced TNM stages and lymph
node metastases. Radical resection significantly decreases the proportions of circulating MDSCs and CD4+CD25highFOXP3+
regulatory T cells. In vitro, CRC cells mediate the promotion of MDSC induction. Moreover, these tumor-induced MDSCs
could suppress T cell proliferation and promote CRC cell growth via cell-to-cell contact. Such effects could be
abolished by the inhibition of oxidative metabolism, including the production of nitric oxide (NO), and reactive
oxygen species (ROS).
Conclusions: Our results reveal the functional interdependence between MDSCs, T cells and cancer cells in CRC
pathogenesis. Understanding the impact of MDSCs on T cells and tumor cells will be helpful to establish an
immunotherapeutic strategy in CRC patients.
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Colorectal cancer (CRC) is the fourth most commonly
diagnosed cancer worldwide and is a major cause of
cancer-related deaths [1,2]. Numerous studies have dem-
onstrated a link between chronic inflammation and dif-
ferent cancers, including CRC. The intestinal mucosa is
normally maintained in a state of controlled inflamma-
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unless otherwise stated.immunity and tolerance to self-antigens and commensal
bacteria [3,4]. An imbalance in the immune tumor micro-
environment is one risk factor for CRC, and the presence
of tumor-infiltrating lymphocytes (TILs) could predict the
clinical outcomes of patients with CRC [5-7]. Accumulat-
ing evidence indicates that subsets of immune cells, in-
cluding cytotoxic T cells (CTLs), natural killer (NK) cells,
and regulatory T cells (Tregs), play important roles in the
progression of CRC and are associated with tumor inva-
siveness, clinical stage, and patient survival [8-10].
Recent studies suggested that myeloid-derived suppressor
cells (MDSCs) play important roles in cancer patients.
MDSCs are an immature population of myeloid cells that
are present in the majority of cancer patients [11]. MDSCsl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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MDSCs (M-MDSCs) and granulocytic MDSCs (G-MDSCs)
[12,13]. In humans, MDSCs constitute a heterogeneous cell
population that is not well characterized, partially because
no unified markers are currently available for these cells.
However, these cells typically express the common myeloid
markers CD33 and CD11b but lack markers of mature
myeloid cells, such as HLA-DR. Among human MDSCs,
the monocytic subset comprises CD14+ cells, and the gran-
ulocytic subset comprises CD14−CD15+ cells [14].
A number of studies have shown that MDSCs are cor-
related with the development of malignancies. Increased
numbers of MDSCs have been observed in various solid
and hematologic malignancies, and elevated MDSCs are
associated with cancer progression and tumor-induced
immune dysfunction [13,15-19]. MDSCs could inhibit
anti-tumor immunity by suppressing T cell and NK cell
functions [20,21], likely by increasing the production of
arginine, reactive oxygen species (ROS), and nitric oxide
(NO) and by inducing Treg cells and TGF-β secretion to
mediate T cell suppression [19,22-24]. In addition to
suppressing anti-tumor immunity, the direct interaction
between MDSCs and tumor cells has been explored in
recent years [25]. However, the specific signals triggering
the accumulation of MDSCs in cancer patients remain
unidentified, and the mechanism of the tumor-induced
MDSC function in CRC is not yet well defined.
In this study, we examined the correlation between
MDSCs and tumor progression in CRC patients and
during routine treatment. We also studied how MDSCs
interact with T cells and CRC cells in vitro.
Materials and methods
Samples and cell lines
Peripheral blood was collected from 32 age-matched
healthy donors and 42 patients with CRC at the time of
first diagnosis at Sun Yat-Sen University Cancer Center,
Guangzhou, China, from March 2013 to June 2013;
these patients did not receive any pre-operative chemo-
radiotherapy. The clinical details of the patients are pro-
vided in Additional file 1: Table S1. Peripheral blood was
collected from 26 of the 42 patients who did not show
any signs of infection, inflammation, or other complica-
tions before or after tumor curative resection one week
after the operation. Fresh tumor and paraneoplastic tis-
sues were obtained from 19 of the patients. All the
tumor tissue samples were removed by surgical resec-
tion; three were collected by palliative resection, and 16
were collected by curative resection. All of the patients
and healthy donors provided written informed consent
before being subjected to blood sampling and/or tumor
harvesting. This study was approved by the Research
Ethics Committee of the Sun Yat-Sen University Cancer
Center.Peripheral blood mononuclear cells (PBMCs) were
isolated via Ficoll-Hypaque gradient centrifugation to
measure the proportion and phenotype of MDSCs. Fresh
tumor and paracancerous tissues were cut into pieces;
one piece was frozen at −80°C for subsequent qRT-PCR
or immunochemical staining, and the other piece was
enzymatically digested with type IV collagenase for
2 hours at 37°C in a water bath oscillator. Bulk cells
from tissues were cultured in complete RPMI 1640
medium (Gibco, Life Technologies, USA) supplemented
with heat-treated 10% fetal bovine serum (FBS, exCell
Biology, South America) without IL-2 overnight to ob-
tain a sufficient number of cells for FACS analysis.
The human SW480 and SW620 colorectal cancer cell
lines were maintained in our laboratory and cultured in
RPMI 1640 supplemented with 10% FBS and gentamicin
sulfate (Guangdong Succhi Shiqi Pharmaceutical, China).
Antibodies and fluorescence-activated cell sorting (FACS)
analysis
Human monoclonal antibodies against HLA-DR, CD4,
CD33, CD11b, CD45, CD8, CD25, CD3, CD16, FOXP3,
CD14, CD15, CD39, CD73, CD117, CD66b, CXCR4,
CD34, arginase1 (ARG1), iNOS and PD-L1 conjugated with
different fluorescent dyes were purchased from BD Phar-
mingen (San Jose, CA, USA) or eBioscience (San Diego,
CA, USA). The oxidation-sensitive dye CM-H2DCFDA
was purchased from Invitrogen (Grand Island, NY).
The expression of markers on the MDSCs and tumor
cells was investigated using FACS analysis after surface
staining or intracellular staining with human-specific
Abs conjugated with different fluorescent dyes. The
MDSC phenotype analysis involved gating within the
HLA-DR− cell population that expressed both the CD33
and CD11b antigens. Intracellular staining to detect
Foxp3 was performed on T cells from PBMCs, tumorous
tissues, and paracancerous tissues. After washing, the
cells were stained with anti-CD4, fixed, permeabilized
with Perm/Fix solution (eBioscience), and stained intra-
cellularly with anti-Foxp3. The cells showing positive
staining were detected using the Cytomics FC 500 MPL
flow cytometry system (Beckman Coulter) and analyzed
with CXP software (Beckman Coulter, Inc. Fullerton,
CA, USA).
Induction of MDSCs and functional analysis of tumor-
induced MDSCs in vitro
CD33+ cells were separated from healthy PBMCs using
human CD33 MicroBeads (Miltenyi Biotec, Bergisch
Gladbach, Germany) according to the manufacturer’s in-
structions. Isolated CD33+ cells were co-cultured with
SW480 or SW620 cells in 24-well plates in a Transwell
System at a ratio of 1:5 for 48 h. CD33+ cells cultured in
medium alone were included as a control. A panel of
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using FACS, and the remaining cells were subjected to the
proliferation assay. In brief, PBMCs from healthy donors
were labeled with CFSE (5 μM) and added in different ra-
tios to the induced MDSCs in OKT3-coated 96-well
plates. The cells were cultured for 3 days. The experiments
included a panel of samples treated with NG-Monomethyl-
L-arginine (1 mM/mL), L-NG-Monomethylarginine (L-
NMMA, 100 μm/mL), or N-acetylcysteine (NAC 1 mM/mL,
Sigma, Saint Louis, MO, USA), which lead to arginine star-
vation and inhibition of the generation of NO and ROS, or
with human TGF-β neutralizing antibody (10 μg/mL;
R&D Systems, Minneapolis, MN, USA) [26,27]. These
samples were analyzed using FACS.
The proliferation of SW480 cells with co-cultured
tumor-induced MDSCs was assessed by counting the
cells from day 1 to day 5 directly, in a Transwell System,
or alone in medium. This experiment included a panel
of samples treated with supplementary L-arginine, L-
NMMA, and NAC.
Semi-quantitative RT-PCR (qRT-PCR)
Total RNA from cells or from frozen tumorous and
paracancerous tissues was extracted using the TRIzol re-
agent (Invitrogen, USA) according to the manufacturer’s
instructions. RT-PCR was performed with the RevertAid
First-Strand cDNA Synthesis kit (Thermo Scientific,
Lithuania) using Premix Taq™ (TaKaRa Taq™ Version 2.0
plus dye). The primer sequences are given in Additional
file 1: Table S2. The obtained PCR products were exam-
ined via agarose gel electrophoresis. All of the tests were
repeated at least 5 times, and GAPDH mRNA was used
as a control.
Statistical analysis
All of the in vitro experiments were performed in triplicate
and were repeated at least three times. Representative ex-
periments are shown in the figures. The statistical analysis
was performed with SPSS 13.0 software (SPSS, Chicago,
IL, USA). Numerical data are shown as means ± standard
error of the mean (SEM). Comparisons between two
groups were tested using Student’s t test, and the associ-
ation of the density of MDSCs with the clinical pathologic
features was examined using a Pearson χ2 test and Fisher's
exact test. In all of the analyses, the threshold for signifi-
cance was P < 0.05.
Results and discussion
Results
MDSCs are expanded in CRC patients
Base on previous reports [28-30], in the current study, we
investigated the proportion and distribution of MDSCs
immunophenotyped as CD33+CD11b+ HLA-DR− cells in
CRC patients (n = 42) and compared this with those ofhealthy donors (n = 32). The proportion of MDSCs in per-
ipheral blood from pre-treated CRC patients was signifi-
cantly increased compared with the proportion from
healthy donors (P < 0.05). To explore the distribution
of MDSCs in CRC patients, we further assessed the
proportion of MDSCs in the tumorous tissues and
tumor-adjacent tissues from 19 paired CRC patients.
The proportion of MDSCs was higher in the tumorous
tissues compared with tumor-adjacent tissues (P <
0.05), as shown in Figure 1.
We examined the expression levels of phenotypic
markers in this CD33+CD11b+HLA-DR− MDSC popula-
tion from CRC patients, including the levels of CD14,
CD15, CD66b, CD117, CD73, CD39 CD34, CXCR4, iNOS,
ARG-1, PD-L1 and ROS (Figure 2). The MDSC population
expressed high levels of the monocytic marker CD14, the
chemokine receptor CXCR4, and the ectonucleoside
triphosphate diphosphohydrolase 1 (ENTPD1) CD39, was
well as immune mediators including ARG-1, iNOS, ROS
and the suppressive immune checkpoint molecule PD-L1
but did not express the ecto-5'-nucleotidase CD73; these
molecules are involved in the degradation of immu-
nostimulatory ATP into immunosuppressive adenosine.
The MDSC population expressed moderate levels of the
granulocyte-monocyte progenitor cell markers CD117,
CD34, and CD66b and expressed a weak level of the gran-
ulocytic marker CD15. The MDSCs from the peripheral
blood and tumorous tissue of CRC patients exhibited
similar phenotypic characteristics.
Elevated circulating MDSCs are associated with advanced
disease stage in CRC patients
To investigate the clinical relevance of MDSCs in CRC
patients, we determined the correlations between the pro-
portion of MDSCs among PBMCs and the clinical charac-
teristics of the CRC patients, including age, gender, TNM
stage, tumor size, lymph node metastasis, histological
grade, venous invasion and serum CEA level (Table 1). An
increased proportion of MDSCs among PBMCs was as-
sociated with an advanced TNM stage and with lymph
node metastases (P = 0.020 and 0.008, respectively),
whereas no correlation between the proportion of
MDSCs in PBMCs and the other clinical characteris-
tics, including tumor size, histological, and serum CEA
level, of patients were found.
Tumor resection reduces the circulating MDSCs and Tregs in
CRC patients
Surgery remains the main treatment option for CRC pa-
tients. However, the effect of surgery on the host im-
mune status has not been well studied. To illustrate the
effects of surgery on immune cell subsets, including
MDSC, Treg, CTL, and NK cells, in the lymphatic sys-
tems of patients with CRC, we analyzed variations in the
Figure 1 Distribution of MDSCs in patients with CRC. (A) Gating strategy for the assessment of the MDSC population using flow cytometry.
HLA-DR− cells were gated from live PBMCs, and CD33+CD11b+ cells were further gated as MDSCs. Representative density plots from two CRC
patients and healthy donors are shown. (B) The dot plots represent CD33+CD11b+ MDSC gating from the HLA-DR−CD45+ cell fraction from the
tumorous and paraneoplastic tissues of one CRC patient. (C) Statistical analysis of the percentage of MDSCs among the PBMCs from CRC patients
(n = 42) and healthy donors (n = 32). (D) The proportion of MDSCs was significantly increased in tumorous tissues compared with paraneoplastic
tissues and PBMCs from CRC patients (n = 19). Error bars represent SEM.
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tients with CRC before and after tumor resection. The
proportions of CD33+CD11b+HLA-DR− MDSCs and
CD4+CD25+Foxp3+ Tregs among the PBMCs were
significantly reduced in the CRC patients after the
operation (P = 0.0001 and P = 0.0012, respectively),
whereas no significant differences in the proportions
of CD3+CD8+ CTL or CD3−CD16+ NK cells among
the PBMCs were found before versus after tumor re-
section (Figure 3).
CRC cells promote the induction of MDSC in vitro
Many studies have suggested that cytokines and other
factors secreted by tumor cells can induce the gener-
ation of MDSCs. In agreement with this notion, high ex-
pression levels of VEGF, G-CSF, IL-6, CD73, iNOS, IDO,
and COX-2 were observed in some tumor tissues and
SW480 cells by semi-quantitative RT-PCR. In SW620
cells, the increase in the expression of genes was less sig-
nificant, with only VEGF and COX-2 highly expressed.
No expression of ARG-1 was detected in tumor or para-
neoplastic tissues from patients or in SW480 or SW620
cells, and no expression of IDO was detected in SW480
or SW620 cells. Interestingly, iNOS expression was only
found in tumor tissue from one patient (1/5) and in
SW480 cells (Figure 4A).
Furthermore, we induced the generation of MDSCs
from CD33+ PBMCs by culturing them with SW480 orSW620 cells in a Transwell System for 48 hours. The
proportion of CD33+CD11b+HLA-DR− MDSCs among
the CD33+ PBMCs was significantly higher when CD33+
PBMCs were co-cultured with SW480 or SW620 cells in a
Transwell System compared with CD33+ cells cultured in
medium alone (Figure 4B). These CRC tumor-induced
MDSCs were mononuclear or polymorphonuclear cells, as
shown in Figure 4C by Wright-Giemsa staining. The CRC
tumor-induced MDSCs exhibited high levels of CD14,
CD66b, CD39, CXCR4, CD117, CD34, ARG1, INOS, ROS
and PD-L1 expression but lacked CD15 and CD73 expres-
sion, similar to the MDSC phenotype observed in CRC pa-
tients (Figure 4D) Thus, CRC cells may promote the
expansion of MSDCs in vivo. In addition, the CRC tumor-
induced MDSCs expressed higher levels of immune in-
hibitory molecules, including TGF-β, IDO, IL-10, iNOS,
NOX2, and Arg-1, and no IFN-γ expression compared
with the CD33+ PBMCs cultured in medium alone
(Figure 4E).
Tumor-induced MDSCs suppress the proliferation of T cells
and promote the growth of CRC cell lines
To investigate the function of these CRC tumor-induced
MDSCs, we first analyzed the immunosuppressive func-
tion of the MDSCs on T cell proliferation in a co-culture
system. In SW480 or SW620 cells, the tumor-induced
MDSCs suppressed the proliferation of PBMCs more
strongly than CD33+ cells cultured in medium alone;
Figure 2 (See legend on next page.)
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Figure 2 Phenotypes of HLA-DR−CD33+CD11b+ MDSCs in CRC patients. HLA-DR−CD33+CD11b+ cells were gated as MDSCs from either
PBMCs (A) or tumor tissues (B) from CRC patients. The phenotypes of the MDSCs were analyzed with flow cytometry using multiple anti-human
mAbs against CD14, CD15, CD66b, CD39, CD73, CXCR4, CD117, CD34, ARG1, INOS, PD-L1 and DCFDA as indicated, and the grey curve represents
autofluorescence as a negative control. Representative histograms are shown.
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(Figure 5A-C). In addition to their immunosuppressive
function, these tumor-induced MDSCs promoted the
growth of SW480 and SW620 cells in a coculture system
in vitro, as shown in Figure 5D.Table 1 Correlations between the proportion of circulating











≤60 27 16 11
>60 15 11 4 0.506
Gender
Male 20 12 8
Female 22 15 7 0.749
TNM stage
I-II 24 19 5
III-IV 18 8 10 0.020*
T stage
T2 3 1 2
T3 28 20 8
T4 11 6 5 0.312
(Fisher’s)
Tumor size (cm)
≤5 25 15 10
>5 17 12 5 0.531
Lymph node
metastasis
No 26 21 5
Yes 16 6 10 0.008**
Histological grade
Well/moderate 24 18 6
Poor/undifferentiated 18 9 9 0.116
Venous invasion
No 38 26 12
Yes 4 1 3 0.122
Serum CEA (ng/mL)
≤5 22 16 6
>5 20 11 9 0.336
Note: a4.0% indicates the mean percentage of circulating MDSC; *indicates P< 0.05;
**indicates P< 0.01; determined by Pearson χ2 test and Fisher’s exact test.The function of tumor-induced MDSCs is mainly
dependent on cell-to-cell contact and oxidative
metabolism
We further investigated the molecular mechanisms of
the function of these CRC tumor-induced MDSCs on T
cells and tumor cells. For T cells, because the highly
expressed inhibitory molecules on the MDSCs (Figure 4E)
are linked to the suppression of T cell proliferation [31,32],
we neutralized these inhibitory molecules by adding sup-
plementary L-arginine, LNMMA, NAC and a neutralizing
TGF-β antibody to the co-culture system. Supplementary
L-arginine, LNMMA and NAC, which are inhibitors for
iNOS and ROS, respectively, significantly reduced the im-
munosuppressive function of the CRC tumor-induced
MDSCs (P < 0.05). However, neutralizing TGF-β antibody
only slightly rescued the inhibition of CD4+ and CD8+ T
cells by these tumor-induced MDSCs. In addition, the
inhibition of CD4+ and CD8+ T cells by these tumor-
induced MDSCs was reversed when a Transwell insert was
used in the co-culture system of T cells and MDSCs, indi-
cating that the immunosuppressive function of MDSCs
was dependent on a cell-to-cell contact manner and oxi-
dative metabolism which is in line with previous reports
(Figure 6A) [14,33]. Moreover, the CRC tumor-induced
MDSCs did not induce Treg cell expansion in vitro
(Figure 6B). For tumor cells, we observed that the promo-
tion of tumor growth induced by MDSCs was inhibited
when the CRC cell lines SW480 and SW620 were co-
cultured with tumor-induced MDSCs in a Transwell Sys-
tem (Figure 6C), indicating that the promotion of tumor
cell growth by MDSCs is dependent on cell-to-cell contact.
Next, we observed that the specific inhibitors LNMMA
and NAC for iNOS and ROS, respectively, significantly
reduced the promoting effect of CRC tumor-induced
MDSCs on the growth of SW480 and SW620 cells (P <
0.05, Figure 6D).
Discussion
The current studies examined the distribution and pheno-
typic markers of MDSCs in human CRC patients and how
MDSCs interact with other cell populations in the CRC
microenvironment, including cancer cells, cytotoxic T cells,
and Treg cells. As with other human cancers, including
breast cancer, gastric cancers, and murine cancers [34-36],
we observed an expansion of MDSCs among PBMCs and
tumorous tissues from patients with CRC. The increased
circulating MDSC population correlated with advanced
disease stages and tumor lymph node metastases in CRC
Figure 3 Decreased proportions of circulating HLA-DR−CD33+CD11b+ MDSCs and CD4+CD25highFOXP3+ Treg cells in CRC patients after tumor
resection. PBMCs were isolated from 26 CRC patients before and after surgery. (A-D) Representative density plots of circulating HLA-DR−CD33+CD11b+
MDSCs, CD4+CD25highFOXP3+ Tregs, CD3+CD4+ T cells, CD3+CD8+ T cells, and CD3−CD16+ NK cells from one CRC patient before and after surgery are
shown. (E-H) The graph shows that the proportions of circulating MDSCs and Tregs were significantly decreased after surgery (P< 0.05), whereas the
proportions of CD3+CD4+ T cells, CD3+CD8+T cells, and CD3−CD16+ NK cells were not significantly different after the operation (P> 0.05).
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(iMC) markers, including CD34, CD33, the macrophage/
DC marker CD11b, and IL4Rα (CD124); however, MDSCs
typically do not express the lineage (Lin) markers of
DCs or other mature myeloid cells [10,12]. Typically,
the CD33+Lin−HLA-DR-/low cells represent a general
expanded MDSC subset in human cancers [37]. Here,
our data suggest that the majority of the CD33+CD11b+
HLA-DR− MDSCs observed in CRC consisted of a mo-
nocytic MDSC subset (CD14+CD15−CD33+CD11b+HLA-
DR−) and an atypical granulocytic MDSC subset. TheseMDSCs express common human immature granulocyte-
monocyte progenitor cell markers, including CD66b;
CD117; CD34; the chemokine receptor CXCR4; CD39, an
enzyme involved in the production of immunosuppressive
adenosine; the immune mediators Arg-1, iNOS and ROS
and the suppressive immune checkpoint molecule PD-L1;
there was no expression of CD73. This finding contrasted
with the phenotypic characteristics of MDSCs observed in
other cancers, such as breast cancer [35], indicating that
MDSCs are heterogeneous in different cancers. The
analogous phenotypic characteristics of the MDSCs in
Figure 4 (See legend on next page.)
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Figure 4 Molecular characteristics of CRC cells and the induction of MDSCs via SW480 or SW620 cells in vitro. (A) The expression of VEGF, G-CSF,
IL-6, IL-37, CD73, iNOS, IDO, and COX2 in in SW480 and SW620 cells and in tumor and paraneoplastic tissues from 5 CRC patients was measured using
quantitative RT-PCR. GAPDH expression was included as a control. (B) CD33+ cells were isolated from healthy PBMCs using human CD33 MicroBeads and
were co-cultured with SW480 or SW620 cells. The representative dot plots and statistical graph show the proportion of HLA-DR−CD33+CD11b+ MDSCs
induced from CD33+ cells by co-culture with SW480 or SW620 cells in a Transwell system for 48 hours. The CD33+ cells in medium alone were included
as a control. (C) A representative cytospin of HLA-DR-CD33 + CD11b +MDSCs stained with Wright-Giemsa and identified by the mononuclear or
polymorphonuclear cell nuclear staining (purple) using light microscopy (20 × 0.30 objective magnification) (Nikon Tokyo, Japan). (D) The phenotypes of
the tumor-induced MDSCs were analyzed with flow cytometry using multiple anti-human mAbs against CD14, CD15, CD66b, CD39, CD73, CXCR4, CD117,
CD34, Arg-1, iNOS, PD-L1 and ROS, and the grey curve represents autofluorescence as a negative control. Representative histograms are shown. (E) The
mRNA levels of TGF-β, IDO, IL-10, IFN-γ, iNOS, Arg-1, and NOX2 in the T-MDSC by CRC cells, and CD33+ cells were detected using quantitative RT-PCR;
GAPDH was included as control, and one of 5 experiments is shown here. T-MDSC, tumor-induced MDSCs by CRC cells.
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and the high expression of CXCR4 on MDSCs indicated
that the accumulation of MDSCs in tumorous tissues might
be because of recruitment from the peripheral blood to tu-
mors and aggregation in situ. A recent study discovered
that CXCR2-expressing MDSCs could be tracked from the
peripheral blood to the colonic mucosa according to their
CXCR2 ligands, and these MDSCs were found to promote
colitis-associated tumorigenesis in a mouse model ofFigure 5 The immunological and non-immunological functions of tum
MDSCs on T cells in vitro was measured using a CFSE-labeled PBMC prolife
tumor-induced MDSCs. The CFSE-labeled PBMCs were cocultured with M-M
96-well plates. After 3 days, the cells were collected, stained with anti-hum
proliferation of PBMCs, CD4+ T cells and CD8+ T cells was dramatically supp
representative FACS density plots from one of 5 experiments, (C) A graph
*P < 0.05. (D) Tumor-induced MDSCs promoted the growth of SW480 and
5 × 103 or 2.5 × 103 cells/well and cultured with T-MDSCs for 5 days at diff
every day. The statistical graph shows the mean value of three experiment
was significantly increased compared with the number of SW480 or SW620
*P < 0.05; **P < 0.01.colitis-associated cancer. Additionally, the CXCL12-CXCR4
pathway triggered the accumulation of MDSCs to ovarian
cancer ascites [23,38].
Correlations between the tumor burden and immune
cells have been explored in cancer patients [39,40]. In the
current study, we observed that the percentages of circu-
lating MDSCs and Tregs were significantly decreased in
patients after undergoing resection, whereas the percent-
ages of CTL and NK cells were unchanged, indicating thator-induced MDSCs. The suppressive ability of the tumor-induced
ration assay. M-MDSC: CD33+ cells cultured in medium alone; T-MDSC:
DSCs or T-MDSCs at a ratio of 1:1 or 1:2, respectively, in OKT3-coated
an mAbs against CD4 and CD8 and quantified via flow cytometry. The
ressed by T-MDSCs compared with M-MDSCs. (A and B) Shown are
of the statistical analyses is shown. The error bars represent the SEM.
SW620 cells. SW480 or SW620 cells were seeded into a 96-well plate at
erent ratios or in medium alone. The number of cells was counted
s. The number of SW480 or SW620 cells after coculture with T-MDSCs
cells cultured in medium alone. The error bars represent the SEM.
Figure 6 The mechanisms of the immunological and non-immunological functions of tumor-induced MDSCs. (A) The inhibition of T cell
proliferation by tumor-induced MDSCs was rescued by a Transwell insert (put MDSC in inner well and PBMC in outer well) and inhibitors of L-Arg,
iNOS and ROS, but not by anti-TGF-β. The statistical graph shows the mean value of 5 experiments. *P < 0.05. (B) CD4+ T cells were co-cultured
with T-MDSC and CD33+ cells or in IL-2 medium alone in an OKT-3 stimulated 48-well cell plate for 3 days and then stained with anti-CD4,
anti-CD25, and anti-FOXP3. The cells were analyzed using flow cytometry. One representative dot plot of three experiments is shown. (C) The
tumor-induced MDSCs promoted the growth of SW480 and SW620 cells via a cell-to-cell contact-dependent mechanism. The cells were seeded
into a 96 or 48-well plate at 5 × 103cells/well and were co-cultured with T-MDSCs at a 1:1 ratio or were co-cultured with T-MDSCs in a Transwell
system for 5 days. The number of SW480 or SW620 cells was significantly increased after co-culture with T-MDSCs compared with the number of
SW480 or SW620 cells cultured in medium alone or with the number of SW480 or SW620 cells after co-culture with T-MDSCs in the Transwell
system. (D) The promotion of CRC tumor-induced MDSCs on the growth of SW480 and SW620 cells was significantly decreased by the inhibitors
of ROS and iNOS. The error bars represent the SEM. *P < 0.05; **P < 0.01.
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and Treg cell populations in the CRC patients after redu-
cing the tumor burden.
The direct interaction between MDSCs and tumor
cells has been studied extensively, including in CRC
[41,42]. In accordance with previous studies [41,43], high
levels of VEGF, G-CSF, IL-6, CD73, iNOS, and COX-2
were observed in the tumorous tissues from CRC pa-
tients and in SW480 cells. Furthermore, in an in vitro
experimental system, the CRC cell lines SW480 and
SW620 could induce CD33+CD11b+HLA-DR− MDSCs
from CD33+ PBMCs. These tumor-induced MDSCs ex-
press high levels of immune inhibitory molecules, in-
cluding TGF-β, IDO, IL-10, Arg-1, iNOS and NOX2,
and could strongly suppress the proliferation of OKT3-
stimulated CD4+ and CD8+ T cells. These data indicate
that the CRC cells induce functional MDSCs in vitro,which is in agreement with previous reports for other
types of cancer cells [17,44]. These tumor-induced
MDSCs suppressed the proliferation of T cells and pro-
moted the growth of SW480 and SW620 cells in a co-
culture system in vitro, indicating that the mutual inter-
action of MDSCs with tumor cells as well as the interaction
of MDSCs with T cells contributed to tumor development
and disease progression in CRC. The promotion of tumor
cell growth by MDSCs was recently reported in multiple
myeloma [25]. Our data demonstrated for the first time
that the promotion of tumor cell growth by MDSCs is
dependent on a cell-to-cell contact mechanism in a Trans-
well System in vitro. Using neutralizing molecules, our
data suggested that CRC tumor-induced MDSCs inhibited
T cell proliferation and promoted CRC cell growth
through oxidative metabolism, including the generation of
NO and ROS, but not through TGF-β signaling or
OuYang et al. Journal of Translational Medicine  (2015) 13:47 Page 11 of 12inducible Treg cells. Overall, these observations indicated
that MDSCs promoted tumor cell growth through a direct
interaction with tumor cells and the suppression of T cell
anti-tumor immunity.
Conclusions
The present study for the first time identifies a func-
tional dependence between MDSCs, T cells and tumor
cells in CRC: tumor cells induce the expansion of MDSCs
via multiple inflammatory factors, and then these tumor-
derived MDSCs suppress T cell proliferation and promote
tumor cell growth through oxidative metabolism. Under-
standing the interactions between tumor cells and MDSCs
may aid in the development of novel therapeutic ap-
proaches for CRC patients.
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